Syndax Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
35 Gatehouse Dr Fl 3 Bldg D, Waltham, Ma...Phone Number
(781) 419-1400Website
www.syndax.comRevenue
$217.2 MillionStock Symbol
SNDXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company incorporated in 2005 and headquartered in New York, New York, focused on the discovery, development, and commercialization of therapies for cancer. The company specializes in oncology, with a primary focus on acute leukemias and chronic graft-versus-host disease. Its pipeline includes a menin inhibitor approved for the treatment of relapsed or refractory acute leukemias driven by specific genetic mutations, as well as a monoclonal antibody targeting the CSF-1 receptor for chronic graft-versus-host disease and additional cancer indications. Syndax is advancing its transition to a fully integrated commercial biopharmaceutical organization, with ongoing clinical development programs across hematologic malignancies and other serious conditions. The company trades on the NASDAQ under the ticker symbol SNDX.Explore more
Syndax Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syndax Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Syndax Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Syndax Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Syndax Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Syndax Pharmaceuticals has new funding data
Earning: See what the market has to say on Syndax Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Syndax Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check if Syndax Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Syndax Pharmaceuticals launches new products
Recommended Actions
Reach out to Masked Content who joined Syndax Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Syndax Pharmaceuticals
Compare insights from companies similar to Syndax Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syndax Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Syndax Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Syndax Pharmaceuticals.
Syndax Pharmaceuticals financials insights
Gather financial insights about Syndax Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$26.6M
2014
Debt
$4.9M
2015
Series C
$80M
2016
Stock Offering
$50.5M
2017
Stock Offering
$48.7M
Stock Offering
$25M
2019
Stock Offering
$26.2M
2020
Multiple Rounds
$323.8M
Syndax Pharmaceuticals Tech Stack
A closer look at the technologies used by Syndax Pharmaceuticals
Most Recent Scoops
Project
Syndax Pharmaceuticals has announced in collaboration with the Hovon Group, is conducting the Evolve 2 evaluating Revumenib added to Vanaza (Venetoclax-based therapy) in AML patients not considered fit for intensive chemotherapy, with dual independently powered primary endpoints of complete response and overall survival, with enrollment underway across multiple international sites since May 2025.
Clinical Operations
Project
Syndax Pharmaceuticals is advancing a placebo-controlled study of Axitilumab in idiopathic pulmonary fibrosis (IPF), supported by preclinical evidence demonstrating that CSF1R inhibition reduces inflammatory cytokines including TGF-beta, TNF, and IL-8, as well as clinical observations showing a 50% improvement in response rate in bronchiolitis obliterans syndrome.
Medical Research, Clinical Operations
Project
Syndax Pharmaceuticals is conducting the Reveal study, evaluating Revumenib in combination with standard seven-plus-three intensive chemotherapy versus chemotherapy alone in NPM1-positive AML patients fit for intensive chemotherapy, with dual independently powered primary endpoints of MRD-negative complete response and event-free survival, including international site activations in Asia.
Clinical Operations
Project
Syndax Pharmaceuticals has announced that in collaboration with MD Anderson Cancer Center, presented data at ASCO on approximately 24 adult and pediatric patients treated with Revumenib maintenance therapy following transplant, demonstrating one- and two-year overall survival rates of approximately 90%, compared to historical controls of approximately 50% to 60%, with thrombocytopenia identified as the most common adverse event and manageable through dose adjustments.
Medical Research, Pharmaceuticals
Partnership
Partnership, Medical Research, Pharmaceuticals, Clinical Operations
Syndax Pharmaceuticals News & Media
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event
– Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs –Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2026, the Company granted inducement awards to purchase up to 250,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencementSyndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations –Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) –
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syndax Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company incorporated in 2005 and headquartered in New York, New York, focused on the discovery, development, and commercialization of therapies for cancer. The company specializes in oncology, with a primary focus on acute leukemias and chronic graft-versus-host disease. Its pipel... Read More
